X-linked distal spinal muscular atrophy type 3

X-linked distal spinal muscular atrophy type 3 (also known as X-linked distal SMA 3, or SMAX3) is a rare inherited neuromuscular disorder characterized by progressive weakness and wasting (atrophy) of the distal muscles, particularly those in the hands and feet. The condition is caused by mutations in the ATP7A gene located on the X chromosome, which encodes a copper-transporting ATPase. Because of its X-linked recessive inheritance, the disease predominantly affects males, while females are typically carriers who may be asymptomatic or mildly affected. The disease primarily affects the peripheral nervous system, specifically the lower motor neurons in the spinal cord that control voluntary movement. Key clinical features include progressive weakness and atrophy of distal limb muscles, leading to difficulties with fine motor tasks and walking. Patients may also develop foot deformities such as pes cavus and hammer toes. The onset of symptoms is typically in childhood or adolescence, and the disease tends to progress slowly. Unlike some other conditions caused by ATP7A mutations (such as Menkes disease), X-linked distal SMA type 3 does not typically involve severe copper metabolism abnormalities or intellectual disability. There is currently no cure or disease-specific treatment for X-linked distal spinal muscular atrophy type 3. Management is supportive and symptomatic, focusing on physical therapy, occupational therapy, orthopedic interventions for foot deformities, and assistive devices to maintain mobility and function. Regular monitoring by a multidisciplinary team including neurologists, geneticists, and rehabilitation specialists is recommended to address evolving symptoms and optimize quality of life.

Common questions about X-linked distal spinal muscular atrophy type 3